Trials / Completed
CompletedNCT04412018
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that will enroll approximately 100 adult outpatients in Canada who have received a positive SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1) to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) or usual care. Blood samples will be collected to determine if icosapent ethyl use lowers circulating pro-inflammatory biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icosapent ethyl | Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) |
Timeline
- Start date
- 2020-06-04
- Primary completion
- 2020-11-06
- Completion
- 2020-12-12
- First posted
- 2020-06-02
- Last updated
- 2021-12-22
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04412018. Inclusion in this directory is not an endorsement.